Clinuvel Pharmaceuticals Limited Stock Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.900 EUR | -1.37% |
|
-5.60% | -15.71% |
| Market Cap | 500M 349M 305M 282M 260M 489M 33.64B 3.37B 1.32B 16.47B 1.31B 1.28B 56.71B | P/E 2026 * |
13.9x | P/E 2027 * | 13.1x |
|---|---|---|---|---|---|
| Enterprise Value | 247M 172M 150M 139M 128M 241M 16.58B 1.66B 653M 8.12B 647M 632M 27.95B | EV / Sales 2026 * |
2.48x | EV / Sales 2027 * | 2.03x |
| Free-Float |
83.79% | Yield 2026 * |
0.62% | Yield 2027 * | 0.81% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | -1.37% | ||
| 1 week | -5.60% | ||
| Current month | -0.84% | ||
| 1 month | +1.69% | ||
| 3 months | +10.28% | ||
| 6 months | -18.62% | ||
| Current year | -15.71% |
| 1 week | 5.9 |  | 6.25 |
| 1 month | 5.7 | | 6.25 |
| Current year | 5.1 | | 7.39 |
| 1 year | 5.1 | | 7.68 |
| 3 years | 4.8 | | 12.68 |
| 5 years | 4.8 | | 27 |
| 10 years | 3.12 | | 27 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.37% | -5.60% | - | - | 349M | |
| -0.33% | +1.83% | +23.03% | -6.22% | 68.85B | |
| +0.67% | +0.93% | +37.53% | +198.53% | 52.13B | |
| +0.94% | +39.60% | +39.60% | +39.60% | 43.46B | |
| +1.12% | +0.35% | -50.35% | -52.35% | 41.24B | |
| -1.40% | +3.43% | +60.07% | -26.01% | 30.41B | |
| -2.11% | -9.45% | +91.99% | -49.58% | 24.53B | |
| +0.51% | +0.46% | +70.08% | +91.96% | 23.42B | |
| -5.57% | -0.84% | -0.17% | +174.11% | 19.75B | |
| -0.86% | -1.99% | +68.42% | +124.39% | 16.57B | |
| Average | -0.84% | -0.81% | +37.80% | +54.94% | 35.6B | |
| Weighted average by Cap. | -0.34% | -0.07% | +31.34% | +47.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.46M 69.45M 60.69M 56.01M 51.62M 97.3M 6.69B 669M 263M 3.28B 261M 255M 11.28B | 105M 73.57M 64.29M 59.33M 54.68M 103M 7.08B 709M 279M 3.47B 276M 270M 11.94B |
| Net income | 35.97M 25.11M 21.95M 20.25M 18.67M 35.19M 2.42B 242M 95.21M 1.18B 94.32M 92.25M 4.08B | 38.2M 26.67M 23.31M 21.51M 19.83M 37.37M 2.57B 257M 101M 1.26B 100M 97.98M 4.33B |
| Net Debt | -254M -177M -155M -143M -132M -248M -17.06B -1.71B -672M -8.36B -665M -651M -28.76B | -286M -200M -175M -161M -148M -280M -19.23B -1.93B -757M -9.42B -750M -734M -32.43B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/07/26 | €5.900 | -1.37% | 358 |
| 16/07/26 | €5.982 | -4.29% | 0 |
| 15/07/26 | €6.250 | 0.00% | 0 |
| 14/07/26 | €6.250 | 0.00% | 0 |
| 13/07/26 | €6.250 | 0.00% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
